Literature DB >> 11549823

Helicobacter pylori therapy: first-line options and rescue regimen.

J P Gisbert1, J M Pajares.   

Abstract

In the present paper, several points regarding Helicobacter pylori treatment are reviewed, with the following conclusions: (1) all different proton pump inhibitors (PPIs) are equivalent when prescribed with antibiotics; (2) ranitidine bismuth citrate is equal to or, in some cases with antibiotic resistance, more effective than PPI; (3) previous treatment with PPI does not seem to affect the rate of eradication obtained with PPI plus two antibiotics; (4) just 1 week of PPI is enough to obtain duodenal ulcer healing, provided that H. pylori eradication is achieved; (5) the eradication rates seem to be higher in peptic ulcer than in nonulcer dyspepsia; (6) in areas where the prevalence of metronidazole resistance is high, triple therapy including a PPI, clarithromycin, and amoxicillin is the best option, and (7) quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is the recommended second-line therapy after PPI-clarithromycin-amoxicillin failure, although replacing the PPI and the bismuth compound by ranitidine bismuth citrate achieves also good results. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549823     DOI: 10.1159/000050668

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  14 in total

1.  Chemometric descriptors in modeling the carbonic anhydrase inhibition activity of sulfonamide and sulfamate derivatives.

Authors:  Brij Kishore Sharma; Pradeep Pilania; Kirti Sarbhai; Prithvi Singh; Yenamandra S Prabhakar
Journal:  Mol Divers       Date:  2009-08-06       Impact factor: 2.943

2.  Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.

Authors:  Guofei Dai; Ni Cheng; Lei Dong; Mutsumi Muramatsu; Shudong Xiao; Ming-Wei Wang; De-Xu Zhu
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori.

Authors:  Erik Glocker; Marco Berning; Monique M Gerrits; Johannes G Kusters; Manfred Kist
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Treatment of Helicobacter pylori Eradication Failures.

Authors:  Javier P. Gisbert; José María Pajares
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

5.  Helicobacter pylori antibiotic resistance in Iran.

Authors:  Marjan Mohammadi; Delaram Doroud; Nazanin Mohajerani; Sadegh Massarrat
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

Review 6.  Potent gastric acid inhibition in Helicobacter pylori eradication.

Authors:  Javier P Gisbert
Journal:  Drugs       Date:  2005       Impact factor: 9.546

7.  Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci.

Authors:  Daiva Dailidiene; M Teresita Bertoli; Jolanta Miciuleviciene; Asish K Mukhopadhyay; Giedrius Dailide; Mario Alberto Pascasio; Limas Kupcinskas; Douglas E Berg
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

8.  Evaluation of the string test for the detection of Helicobacter pylori.

Authors:  Rupert W L Leong; Ching C Lee; Thomas K W Ling; Wai K Leung; Joseph J Y Sung
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 9.  [Eradication and chronic acid suppression. Advances and pseudo-advances].

Authors:  S Turi; D Schilling; J F Riemann
Journal:  Internist (Berl)       Date:  2004-11       Impact factor: 0.743

10.  Cloning, polymorphism, and inhibition of beta-carbonic anhydrase of Helicobacter pylori.

Authors:  Saori Morishita; Isao Nishimori; Tomoko Minakuchi; Saburo Onishi; Hiroaki Takeuchi; Tetsuro Sugiura; Daniela Vullo; Andrea Scozzafava; Claudiu T Supuran
Journal:  J Gastroenterol       Date:  2008-11-18       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.